Parkman Healthcare Partners LLC Purchases 14,670 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Parkman Healthcare Partners LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,840 shares of the company's stock after purchasing an additional 14,670 shares during the quarter. Neurocrine Biosciences makes up approximately 1.9% of Parkman Healthcare Partners LLC's portfolio, making the stock its 17th largest holding. Parkman Healthcare Partners LLC owned 0.13% of Neurocrine Biosciences worth $14,960,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of NBIX. Investment Management Corp of Ontario raised its stake in Neurocrine Biosciences by 33.5% during the 3rd quarter. Investment Management Corp of Ontario now owns 4,778 shares of the company's stock valued at $551,000 after purchasing an additional 1,200 shares during the last quarter. Erste Asset Management GmbH bought a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $2,738,000. True Wealth Design LLC grew its position in Neurocrine Biosciences by 11,740.0% during the third quarter. True Wealth Design LLC now owns 592 shares of the company's stock worth $68,000 after buying an additional 587 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of Neurocrine Biosciences by 12.3% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 736,910 shares of the company's stock valued at $84,907,000 after buying an additional 80,792 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in Neurocrine Biosciences in the 3rd quarter valued at $1,717,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on NBIX shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Barclays decreased their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Raymond James reissued an "outperform" rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Jefferies Financial Group upped their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research note on Monday, August 19th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Trading Up 1.8 %

Shares of NBIX traded up $2.30 during trading hours on Wednesday, reaching $127.74. The stock had a trading volume of 660,505 shares, compared to its average volume of 872,627. The company has a market capitalization of $12.93 billion, a price-to-earnings ratio of 33.63 and a beta of 0.34. The firm has a 50-day simple moving average of $119.60 and a 200 day simple moving average of $131.25. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now owns 15,449 shares of the company's stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.